SCHEMBL20625899

SCHEMBL20625899

O=C1N[C@H](CCCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.68
ACHE P22303 2/20 0.68
PDPK1 O15530 1/20 0.38
MTOR P42345 1/20 0.38
PSEN1 P49768 3/20 0.37
PSEN2 P49810 3/20 0.37
APH1B Q8WW43 3/20 0.37
NCSTN Q92542 3/20 0.37
APH1A Q96BI3 3/20 0.37
PSENEN Q9NZ42 3/20 0.37
FUCA1 P04066 1/20 0.37
MAOB P27338 2/20 0.36
MAOA P21397 1/20 0.36
GPR84 Q9NQS5 3/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
PPARG P37231 1/20 0.34
MAPK10 P53779 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18961290 0.81 BCHE (1.00) BCHEACHEPDPK1MTORPSEN1
SCHEMBL24376571 0.81 BCHE (1.00) BCHEACHEPDPK1MTORPSEN1
SCHEMBL17925924 0.75 BCHE (0.62) BCHEACHEPDPK1MTORPSEN1
SCHEMBL23995897 0.75 BCHE (0.62) BCHEACHEPDPK1MTORPSEN1
SCHEMBL4182846 0.73 BCHE (0.59) BCHEACHEPDPK1MTORPSEN1
SCHEMBL18716356 0.73 BCHE (0.50) BCHEACHEPSEN1PSEN2APH1B
SCHEMBL21944472 0.70 BCHE (0.53) BCHEACHEPSEN1PSEN2APH1B
SCHEMBL18686920 0.70 BCHE (0.53) BCHEACHEPSEN1PSEN2APH1B
SCHEMBL2887472 0.70 BCHE (0.55) BCHEACHEPDPK1MTORPSEN1
SCHEMBL3818662 0.70 BCHE (0.55) BCHEACHEPDPK1MTORPSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174054-B2 Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy AMICUS THERAPEUTICS, INC. (US) 2019-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174054-B2 Compounds and methods for the treatment of Alzheimer's disease and/or cerebral amyloid angiopathy APP, PSEN1, PSEN2 BCHE 23/4885ACHE 85/4885PDPK1 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.